ONE KENDALL SQUARE, CAMBRIDGE, MA
Investor Presentation
Material disclosure
CAMP4 Therapeutics Enters Underwriting Agreement for 5 Million Shares
Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries
Initiates GLP Toxicology Studies for CMP-SYNGAP-01
Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders
Earnings Release
Shareholder votes
Q3
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(4)
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Free Writing Prospectus